KRAS and colorectal carcinoma: On the other hand, 30% to 40% of CRC patients have a v-ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)-driven CRC, which is difficult to target with drugs due to its notorious ‘un-druggable’ property and ineffective response to conventional therapies [2].